

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Highly Specialised Technology Evaluation

Eliglustat for treating type 1 Gaucher disease

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> Genzyme Therapeutics (eliglustat) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> British Liver Trust CLIMB – Children Living with Inherited Metabolic Diseases Contact a Family Gauchers Association Genetic Alliance UK Jewish Genetic Disorders UK Muslim Council of Britain South Asian Health Foundation Specialised Healthcare Alliance <p><u>Professional groups</u></p> <ul style="list-style-type: none"> Association of Genetic Nurses and Counsellors Association of Surgeons of Great Britain and Ireland British Inherited Metabolic Disease Group British Society for Genetic Medicine Royal College of Anaesthetists Royal College of General Practitioners Royal College of Nursing Royal College of Pathologists Royal College of Physicians Royal College of Surgeons Royal Manchester Children’s Hospital Royal Pharmaceutical Society Royal Society of Medicine UK Genetic Testing Network United Kingdom Clinical Pharmacy Association <p>Treatment Centres: Lysosomal Storage Disorders</p> <ul style="list-style-type: none"> Addenbrooke's Lysosomal Disorders Unit Birmingham Children’s Hospital NHS Foundation Trust 	<p><u>General</u></p> <ul style="list-style-type: none"> Allied Health Professionals Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health, Social Services and Public Safety for Northern Ireland Healthcare Improvement Scotland Hospital Information Services – Jehovah’s Witnesses Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Alliance NHS Commercial Medicines Unit NHS Confederation Scottish Medicines Consortium Welsh Government Welsh Urological Society <p><u>Comparator companies</u></p> <ul style="list-style-type: none"> Actelion Pharmaceuticals UK (miglustat) Genzyme Therapeutics (imiglucerase) Shire Human Genetic Therapies UK (velaglucerase alfa) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> Cochrane Metabolic & Endocrine Disorders Group MRC Clinical Trials Unit National Institute for Health Research <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> Public Health England Public Health Wales NHS Trust

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Charles Dent Metabolic Unit, UCLH • Department of Endocrinology, UHBFT • Mark Holland Metabolic Unit for Adult Inherited Metabolic Disorders, SRFT • Metabolic Medicine Unit, GOSH • Royal Free Lysosomal storage disorders unit • Willink Biochemical and Genetics Unit <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • NHS England • NHS Halton CCG • NHS Heywood, Middleton & Rochdale CCG 	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the recommendations.

All non-manufacturer/sponsor consultees are invited to make an evidence submission or submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the recommendations.

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the final evaluation documentation for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary).

All non-manufacturer/sponsor commentators are invited to nominate clinical specialists or patient experts.

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.